home / stock / aps:cc / aps:cc news

APS:CC News and Press, Aptose Biosciences Inc. From 09/14/22

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APS:CC
Market: TSXC
Website: aptose.com
Menu
APS:CC APS:CC Quote APS:CC Short APS:CC News APS:CC Articles APS:CC Message Board
Get APS:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
APS:CC - Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference

SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic m...
APS:CC - Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.

SAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malign...

APS:CC - Aptose's New "G3" Formulation of Luxeptinib Boosts Bioavailability

– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure – – Supports exploration of continuous dosing of G3 formulation – – Lead clinical compound HM43239 continues to progress on schedule – ...

APS:CC - Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic ma...
APS:CC - Aptose Reports Results for the Second Quarter 2022

─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─ ─ HM43239 Complete Remissions and Safety Across Three Dose Levels and Multiple Genotypic Subpopulations ─ ...

APS:CC - Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic ma...

APS:CC - Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter end...
APS:CC - Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic maligna...

APS:CC - CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier t...

APS:CC - Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or th...
Previous 10 Next 10